Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Epix Expanded Agreement With Cystic Fibrosis Foundation Valued At $50 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Extended deal includes potential for $37.7 million in payments to Epix, which is developing 3-D model of key protein associated with CF.

You may also be interested in...



Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?

Marrying off drugs inherited in Predix merger could help firm stay afloat.

Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?

Marrying off drugs inherited in Predix merger could help firm stay afloat.

Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease

10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS067700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel